Patrys logo

Patrys(ASX) PAB

Market CapA$20.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-99%
5 Year-95%
1 Year+100%
1 Month-6%
A$0.03
-6.25%
-0.00Today
Patrys last closing stock price
MetricPriceDate
Last closeAUD 0.032026-10-09
Patrys stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.25%AUD 0.032026-10-02
1 month-6.25%AUD 0.032026-09-09
3 month-25%AUD 0.042026-07-10
Year to date+7.14%AUD 0.032025-12-31
1 year+100%AUD 0.022025-10-09
3 year-75%AUD 0.122023-10-10
5 year-95.35%AUD 0.652021-10-08
Since inception-99.43%AUD 5.302007-07-13

Patrys Financials at a Glance

Market Cap

A$20.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$835.23K

Net Income (TTM)

-A$6.43M

EPS (TTM)

-A$0.01

P/E Ratio

-2.52

Dividend

A$0.00

Beta (Volatility)

0.32 (Low)

Price

A$0.03

Volume

990,343

Open

A$0.03

Previous Close

A$0.03

Daily Range

A$0.03 - A$0.03

52-Week Range

A$0.02 - A$0.05

Estimated Earnings Date

Feb 19, 2026

PAB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Patrys

Patrys Limited is a biotechnology company based in Melbourne, Australia, focused on developing advanced antibody technologies for cancer treatment. The company is known for its innovative therapeutic candidates, including Deoxymab 3E10 and PAT-DX1, which target cancer cells effectively.

Products and Services
  • Deoxymab 3E10: A DNA damage-repair antibody for cancer therapy
  • PAT-DX1: An antibody fragment targeting primary and secondary brain cancers
  • PAT-DX3: A full-sized antibody under evaluation for its therapeutic properties
Growth Outlook
  • Recent advancements in antibody technology position Patrys for significant market opportunities
  • Ongoing clinical evaluations of PAT-DX1 and PAT-DX3 may enhance product pipeline
  • Strategic partnerships could accelerate development and commercialization efforts
Financial Highlights
  • Recent quarterly revenue of AUD 6,686 indicates potential for growth
  • Cash and cash equivalents increased to AUD 3,360,125, providing operational stability
  • Current ratio of 3.84 suggests strong liquidity position
Patrys Limited is dedicated to addressing unmet medical needs in oncology through its innovative antibody technologies. The company's focus on research and development, combined with a robust pipeline, positions it well for future growth. Recent financial data reflects a stable cash position, which is crucial for ongoing operations and development activities. The potential for strategic partnerships and advancements in clinical trials further enhances the company's prospects in the competitive biotechnology landscape.
AI Generated • Sep 24, 2026

Industry

Biotechnology

CEO

Samantha South, PhD, MBA

Headquarters

Nedlands, WA 6009, AU

PAB Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-51217.77%

Net Income Margin

-51070.74%

Return on Equity

-58.53%

Return on Capital

-33.64%

Return on Assets

-30.77%

Earnings Yield

-39.68%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$20.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

674.85M

Volume

990.34K

Avg. Volume

325.13K

Financials (TTM)

Gross Profit

A$835.23K

Operating Income

-A$6.13M

EBITDA

-A$6.06M

Operating Cash Flow

-A$3.94M

Capital Expenditure

-A$3.85K

Free Cash Flow

-A$3.95M

Cash & ST Invst.

A$3.36M

Total Debt

A$0.00

Patrys Performance Analysis

Patrys annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Patrys sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-310.8%
Q42025-06-30-86.6%
Q22025-12-31-100.0%
Q42026-06-30N/A
Patrys annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.04-0.5%
20242024-06-30AUD -0.02-50.0%
20252025-06-30AUD -0.02-15.3%
20262026-06-30AUD -0.01-46.5%
Patrys sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3112.5%
Q42025-06-3014.3%
Q22025-12-31-1783.3%
Q42026-06-3091.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$6.69K

-99.1%

Gross Profit

A$6.69K

-99.1%

Gross Margin

100.00%

N/A

Market Cap

A$20.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.35M

N/A

Employees

15

N/A

Net Income

-A$393.39K

+75.2%

EBITDA

-A$400.07K

+74.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$3.36M

+50.0%

Total Debt

A$0.00

N/A

Accounts Receivable

A$100.54K

-92.5%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-30.77%

N/A

Return on Invested Capital

-33.64%

N/A

Free Cash Flow

-A$1.51M

+31.9%

Operating Cash Flow

-A$1.51M

+32.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BTC.AXBTC Health Limited
A$0.06+0.00%
AGH.AXAlthea Group Holdings Limited
A$0.02-4.76%
IME.AXImExHS Limited
A$0.30+0.00%
MDR.AXMedAdvisor Limited
A$0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About PAB

What is the current price of Patrys?

Patrys is trading at A$0.03 per share.

What is the 52-week range for Patrys?

Over the past 52 weeks, Patrys has traded between A$0.02 and A$0.05.

How much debt does Patrys have?

As of the most recent reporting period, Patrys reported total debt of A$0.00.

How much cash does Patrys have on hand?

Patrys reported A$3.36M in cash and cash equivalents in its most recent financial results.

What is Patrys’s dividend yield?

Patrys does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.